Analysis of the CΥP2D6 gene in relation to dextromethorphan O- demethylation capacity in a Japanese population

Tomonori Tateishi, Michihiro Chida, Noritaka Ariyoshi, Yoshihiro Mizorogi, Tetsuya Kamataki, Shinichi Kobayashi

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Objective: To analyze the CΥP2D6 allele frequencies in a Japanese population and to evaluate the effects of CΥP2D6 variants on in vivo CΥP2D6 activity as measured by the dextromethorphan metabolic ratio (MR). Method: Ninety-eight unrelated, healthy Japanese men were phenotyped with dextromethorphan and genotyped by the polymerase chain reaction amplification method for 7 CΥP2D6 alleles. Results: The CΥP2D6*1, CΥP2D6*10, CΥP2D6*2, CΥP2D6*5, CΥP2D6*4, and CΥP2D6*21 allele frequencies in our Japanese subjects were 0.423, 0.408, 0.092, 0.061, 0.020, and 0.010, respectively. Thirty-three subjects (33.7%) were heterozygous for *10/*1, and 18 (18.4%) and 17 (17.3%) subjects were homozygous for *1 and *10, respectively. Subjects who were homozygous for *10 showed the highest dextromethorphan MR among these 3 genotypes. Eighteen subjects (18.3%) were heterozygous for *2, but their dextromethorphan MR values were not greater than the MR values of subjects who were homozygous for *1. One subject was a poor metabolizer phenotypically, and he was homozygous for *5. Conclusions: The CΥP2D6 allele frequencies in our Japanese subjects differed from those determined in previous studies of white subjects or mainland Chinese subjects. Individuals homozygous for *10 who have relatively low in vivo CΥP2D6 activity represent almost 20% of the Japanese population. In addition, we did not identify any subjects with amplified *2 among our 98 Japanese men.

Original languageEnglish
Pages (from-to)570-575
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume65
Issue number5
DOIs
Publication statusPublished - 1999
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology

Cite this